Skip to content
Artwork for The Lancet in conversation with

The Lancet in conversation with

The Lancet Group

Niall Boyce, Chloe Wilson, and Callum Davidson—editors at The Lancet— in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.

Play
  • 21 episodes
  • Avg 24 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • #8
    October 29 · 22 min

    Do you believe in meta-analysis?

    Niall Boyce welcomes Professor Stuart Pocock, author of two Lancet papers, published 35 years apart: 1991's "Can meta-analyses be trusted?" and 2026's "What makes a meta-analysis believable?" They discuss what makes a trustworthy meta, and how the smart clinician should use the totality of evidence to inform clinical care. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01087-1/fulltext

  • #7
    August 27 · 32 min

    How should we manage cardiovascular conditions in pregnancy?

    What cardiovascular issues can women experience in pregnancy, and why? Lancet editors Niall Boyce and Chloe Wilson talk with Professor Garima Sharma, one of the authors of a new Series of papers aiming to bring the cardiovascular health of pregnant women into the mainstream of primary and secondary care. Click here to read the full series: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01235-3/fulltext https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00190-1/fulltext https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01234-1/fulltext

  • #6
    July 31 · 23 min

    What’s the story with mRNA vaccines?

    What are mRNA vaccine, how do they work, and how might they be used for in the future? And why is there a gap between the evidence and some people’s perception of their safety and efficacy? Niall Boyce from The Lancet talks to Anna Blakney, biomedical engineer and one of the authors of new Review paper "Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective". Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00512-X/abstract

  • #5
    July 10 · 19 min

    What are cardiometabolic long-term conditions?

    What are cardiometabolic long-term conditions? To mark the publication of a new Lancet Series, editors Niall Boyce and Flávia Geraldes talk to Professor Kamlesh Khunti of the University of Leicester. They learn about a new way of conceptualising common medical conditions that has the potential to radically transform both health services and patient outcomes. Click here to read the full series: https://www.thelancet.com/series-do/lancet-series-cardiometabolic-multiple-long-term-conditions

    • Transcript
  • #4
    May 31 · 32 min

    Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology

    In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field. The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era. Visit the lancet.com to discover more

  • #3
    May 19 · 31 min

    Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement

    Do we need to rethink our response to conflict and forced displacement? A new Lancet Commission radically rethinks policy, funding, and practical approaches to humanitarian crises. Chair Professor Paul Spiegel joins Niall Boyce from the Lancet to discuss the aims and recommendations of this Commission on one of the most pressing health issues of the 21st century. Click here to visit the commission page and read the full article: www.thelancet.com/commissions-do/conflict-forced-displacement

  • #2
    May 2 · 31 min

    Can semaglutide be used to treat alcohol use disorder?

    The Lancet’s Niall Boyce and Jonathan Pimm, and eBioMedicine’s Kalypso Karastergiou discuss an exciting new potential treatment for alcohol use disorder: semaglutide. As new research is published in The Lancet, they go behind the headlines with lead author Professor Anders Fink-Jensen to ask what the study showed, and what its implications are for the future of addiction medicine. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext

    • Transcript
  • February 3 · 30 min

    Louise Chappell and Na’ama Carlin on Personal Cancer Stories

    The uniqueness of each patient is at the heart of this year's World Cancer Day. Each cancer patient has their own hopes, dreams and fears. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer care not only on their bodies but also on their lives. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Dec 19, 2025 · 24 min

    Susannah Stanway on the London Global Cancer Week

    In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025. This episode goes beyond event highlights to discuss the need for a global oncology agenda rooted in equity, evidence-based care, and value across care settings. Topics span from geriatric oncology to cardio-oncology, nursing workforce resilience, cancer care in conflict zones, and sustainable health financing, showing how multi-stakeholder collaboration can drive policy and practical improvements, especially in low- and middle-income countries. Listeners will take away practical steps for action: integrating geriatric assessment and baseline cardiovascular risk checks, strengthening cancer registries and national audits, and pursuing domestic funding for universal health coverage. The discussion highlights the urgency of addressing cancer globally including context specific solutions sensitive to local settings and emphasises prevention, early diagnosis, and accessible treatment as core priorities. Click here to visit the London Global Cancer week website Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Dec 9, 2025 · 1 hr 1 min

    Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health

    Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry. Addressing this urgent threat demands a coordinated response from the global public health community. So argues a 3-paper Series published in The Lancet that examines the evidence, proposes policies to halt and reverse the rise in ultra-processed foods, and illuminates the fundamental political and economic drivers at play. Professor Carlos Monterio, Professor Camila Corvalán, and Professor Phil Baker join host Callam Davidson to discuss this powerful and timely Series. Click here to visit the series hub: https://www.thelancet.com/series-do/ultra-processed-food Download the 'Lancet Series on Ultra-Processed Foods and Human Health' infographic here: https://www.thelancet.com/infographics-do/ultra-processed-food-2025 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Dec 7, 2025 · 13 min

    Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma

    Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Oct 19, 2025 · 20 min

    Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

    Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Oct 17, 2025 · 22 min

    Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer

    Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Jul 28, 2025 · 20 min

    Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden

    With the global burden of liver cancer growing, The Lancet has commissioned an international panel of experts to identify strategies to strengthen the prevention, surveillance, diagnosis, and treatment of liver cancer. Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Commission, which is published today on World Hepatitis Day. Read the full Commission: https://www.thelancet.com/commissions-do/hepatocellular-carcinoma?dgcid=buzzsprout_icw_podcast_lancethcc25_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Jul 24, 2025 · 27 min

    Rebecca Fitzgerald on biomarker risk stratification with capsule sponge in the surveillance of Barrett’s oesophagus

    Early detection of oesophageal adenocarcinoma improves outcomes. Patients with the precursor lesion, Barrett's oesophagus, are recommended to undergo regular endoscopic surveillance, a process that can be burdensome for patients and health services. Professor Rebecca Fitzgerald's team have developed a tool that may be able to improve Barrett's surveillance. She joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01021-9/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Jun 11, 2025 · 14 min

    ASCO 2025 Debrief

    Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, and Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference. If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167 Articles discussed in this podcast episode include: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lancet_tlw #asco2025 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • May 31, 2025 · 14 min

    Presented at ASCO: the first RCT of CAR T-cell therapy in solid tumours

    Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

    • Chapters
  • May 30, 2025 · 4 min

    Previewing ASCO 2025

    Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, joins Gavin Cleaver to discuss what's being published at this year's American Society of Clinical Oncology (ASCO) meeting, what she's excited to see at the conference, and why ASCO is so important to the field. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Mar 14, 2025 · 28 min

    Francis Couturaud on treatment of venous thromboembolism

    Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated. Read the full paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02842-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

  • Jan 27, 2025 · 16 min

    Shawn St Peter on appendicectomy versus antibiotics for acute uncomplicated appendicitis in children

    This week, we discuss treatment approaches for uncomplicated appendicitis in children following the publication of a trial in our January 18th issue. Lead author Shawn St Peter, general paediatric surgeon and surgeon-in-chief at Children’s Mercy Hospital, Kansas City, spoke with Callam Davidson about the motivation behind the study, key findings, and what the results mean for clinical practice. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02420-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Showing 1–20 of 21 episodes